| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/20/2008 | WO2008004698A3 Pyrazolo [1, 5-a] pyrimidine compounds as cb1 receptor antagonist |
| 03/20/2008 | WO2008003667A3 Combinations of monoamine reuptake inhibitors and potassium channel activators |
| 03/20/2008 | WO2008003028A3 Pharmaceutical compositions comprising droxidopa |
| 03/20/2008 | WO2008001921A3 Dermatological anti-wrinkle agent |
| 03/20/2008 | WO2008001212A3 Penem prodrugs |
| 03/20/2008 | WO2007149874A8 Imidazolidinone kv1.5 potassium channel inhibitors |
| 03/20/2008 | WO2007149861A3 Soft tissue repair and regeneration using stem cell products |
| 03/20/2008 | WO2007149818A3 Ruminant feedstock dietary supplement |
| 03/20/2008 | WO2007149500A9 Formulations containing hybrid dendrimers |
| 03/20/2008 | WO2007147163A3 Compositions comprising carotenoid analogs or derivatives and methods for synthesis |
| 03/20/2008 | WO2007146795A3 Pharmaceutical formulation for parenteral administration |
| 03/20/2008 | WO2007146440B1 Glucan preparations |
| 03/20/2008 | WO2007146341A9 Amorphous and crystalline forms of pantoprazole magnesium salt |
| 03/20/2008 | WO2007146288A3 Methods for the formulation and manufacture of artesunic acid for injection |
| 03/20/2008 | WO2007146087A3 SUBSTITUTED PYRAZOLO [1,5-α] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE |
| 03/20/2008 | WO2007144512A3 Diazeniumdiolate derivatives, method for the preparation thereof, pharmaceutical compositions thereof, and use of same in the fields of hypertension and cardiovascular pathologies |
| 03/20/2008 | WO2007143724A3 Compositions and methods to enhance reverse cholesterol transport |
| 03/20/2008 | WO2007143131A3 Prednisolone sodium phosphate formulations |
| 03/20/2008 | WO2007142942A3 Method of improving wound healing |
| 03/20/2008 | WO2007141743A3 A tablet dosage form comprising cetirizine and pseudoephedrine |
| 03/20/2008 | WO2007140358A3 Treatment of polyglutamine-expansion neurodegenerative diseases |
| 03/20/2008 | WO2007140174A3 Compounds and methods for modulating fxr |
| 03/20/2008 | WO2007140154A3 Salts and crystal modifications thereof |
| 03/20/2008 | WO2007138110A3 Compounds that interact with ion channels, in particular with ion channels from the kv family |
| 03/20/2008 | WO2007136921A3 Small molecule apoptosis promoters |
| 03/20/2008 | WO2007136696A3 Use of substituted azetidinone compounds with cetp inhibitors for the treatment of sitosterolemia |
| 03/20/2008 | WO2007136510A3 Polymorphic forms of imatinib mesylate and processes for their preparation as well as of amorphous imatinib mesylate and form alpha |
| 03/20/2008 | WO2007136250A3 A pharmaceutical composition suitable for the treatment of cancer and method of preparing said pharmaceutical composition |
| 03/20/2008 | WO2007133983A3 2-aminobenzimidazoles for treating neurodegenerative diseases |
| 03/20/2008 | WO2007132328A3 Novel galenic forms of artemisin and its derivatives in combination with other antimalarial agents for treating malaria |
| 03/20/2008 | WO2007130468A3 Pyrido [2, 3-b] pyrazine and [1, 8] -naphthyridine derivatives as alk and c-met inhibitors |
| 03/20/2008 | WO2007129221A3 Compositions comprising an epi-inositol compounds and methods for treatment of disorders of protein aggregation |
| 03/20/2008 | WO2007129169A3 Cox- ii inhibitors for improving reproductive success in a female animal |
| 03/20/2008 | WO2007125385A3 Treatment of renal disorders, diabetic nephopathy and dyslipidemias |
| 03/20/2008 | WO2007120883A3 Compositions and their uses directed to hepcidin |
| 03/20/2008 | WO2007115058A3 Thiadiazolidinone inhibitors of ptpase |
| 03/20/2008 | WO2007113198A3 Use of a kinase inhibitor for the treatment of particular resistant tumors |
| 03/20/2008 | WO2007109290A3 Water-soluble zinc ionophores, zinc chelators, and/or zinc complexes and use for treating cancer |
| 03/20/2008 | WO2007109248A3 Treatment or prevention of scarring, capsular contractures and/or hyperpigmentation using leukotriene receptor antagonist and vitamin e |
| 03/20/2008 | WO2007107664A3 Use of e-3-[3-[n-(4-methoxybenzenesulfonyl)-n-isopropylamino]phenyl]-3-(3-pyridyl)propenohydroxamic acid for preparing a medicament for preventing and/or treating inflammatory skin pathologies |
| 03/20/2008 | WO2007104422A3 Agent-enriched nanoparticles based on hydrophilic proteins |
| 03/20/2008 | WO2007103782A3 Pharmaceutical latrunculin formulations |
| 03/20/2008 | WO2007103250A3 Thiadiazole compounds and their use in phototherapy |
| 03/20/2008 | WO2007103185A3 Sustained release dosage forms of analagesic medications |
| 03/20/2008 | WO2007098278A3 Inhibitors of pai-1 for treatment of muscular conditions |
| 03/20/2008 | WO2007092861A3 Inhibitors specific of presenilin-1 and their uses |
| 03/20/2008 | WO2007084861A3 Xenohormesis based compositions and methods |
| 03/20/2008 | WO2007084684A3 Therapeutic uses of inhibitors of rtp801 |
| 03/20/2008 | WO2007084391A3 Thiazole compounds as protein kinase b ( pkb) inhibitors |
| 03/20/2008 | WO2007083119A3 Methods |
| 03/20/2008 | WO2007077531A3 Quinaldine based semisquaraines and squaraine dyes, process for preparation thereof and use thereof |
| 03/20/2008 | WO2007072219A3 Alpha enolase-directed diagnostics and therapeutics for cancer and chemotherapeutic drug resistance |
| 03/20/2008 | WO2007072092A8 New phenanthridine derivatives as bradykinin antagonists |
| 03/20/2008 | WO2007068462A3 Mtor inhibitors for the treatment of inflammatory bowel disease |
| 03/20/2008 | WO2007066197A3 Immunomodulatory pharmaceutical composition containing a combination of three coumarinolignoids |
| 03/20/2008 | WO2007064755A3 Treatment of xerostomia with a sulfur-containing antioxidant |
| 03/20/2008 | WO2007054303A3 Diaryl urea for treating diabetic neuropathy |
| 03/20/2008 | WO2007053502A3 Mutations and polymorphisms of hdac5 |
| 03/20/2008 | WO2007052076A3 Formulations comprising jorumycin-, reni eramycin-, safracin- or saframycin-related compounds for treating proliferative diseases |
| 03/20/2008 | WO2007023396A3 Vasoactive kit and composition and uses thereof |
| 03/20/2008 | WO2007022734A8 A composition for alleviating a hangover comprising hyaluronic acid and activated carbon |
| 03/20/2008 | WO2007022042A3 Combinations comrising a protein kinase inhibitor being a pyrimidylaminobξnzamide compound and a hsp90 inhibitor such as 17-aag |
| 03/20/2008 | WO2007010501A3 A pharmaceutical composition comprising a combination of beta blocker and an ace inhibitor |
| 03/20/2008 | WO2006125166A9 Pharmacological modulation of telomere length in cancer cells for prevention and treatment of cancer |
| 03/20/2008 | WO2006094187A3 Phthalazine, aza- and diaza-phthalazine compounds and methods of use |
| 03/20/2008 | WO2001025398A3 Process for inducing functional tolerance to gene transfer products |
| 03/20/2008 | WO2001003644A3 Pyrazolopyrimidinone derivatives conjugated to thiophene moieties or benzo [fused] 5-membered heterocycles for erectile dysfunction |
| 03/20/2008 | US20080071233 Pharmaceutical compositions |
| 03/20/2008 | US20080071229 Process for preparation of antimicrobial plastics compositions |
| 03/20/2008 | US20080071093 Forming, purification of dipyrromethane and porphrin ; condensation, oxidation, cyclization |
| 03/20/2008 | US20080071088 Drugs for respiratory system disorders; also chemical intermediate for such drugs |
| 03/20/2008 | US20080071083 Methods for minimizing thioamide impurities |
| 03/20/2008 | US20080071069 For delivering DNA/RNA into cells |
| 03/20/2008 | US20080071068 Cytoplasmic Localization Dna and Rna |
| 03/20/2008 | US20080070991 improving the bioavailability of resveratrol by including a bioadhesive promoter; organic or synthetic resveratrol, genetic engineering or nanotechnology product; protect from atherosclerosis, hyperlipidemia, cardiovascular disease, cancer |
| 03/20/2008 | US20080070990 Use of ractopamine enantiomers |
| 03/20/2008 | US20080070989 Method of Evaluating Evenness of Suplatast Tosilate Crystal, Even Crystal, and Process for Producing the Same |
| 03/20/2008 | US20080070988 Method of Enhancing Hair Growth |
| 03/20/2008 | US20080070987 [{3-[(propionylamino)methyl]phenyl}methanammonium]6[V10O28]6-; semicarbazide-sensitive amine oxidase (SSAO)/Vascular Adhesion Protein-1 (VAP-1) agonist; antidiabetic, elevated plasma glucose levels, and ketoacidosis; "insulin mimetics", increase cells' sensitivity for glucose uptake |
| 03/20/2008 | US20080070986 surfactants esters of citric acid with ethoxylated fatty alcohols for applying to skin, preventing pathogenic bacteria like Propionibacterium, Staphylococcus; without impairing the natural balancing processes, maintain natural pH value (acid protection jacket of the skin) |
| 03/20/2008 | US20080070984 antipsychotic drug mixture contains the active drug, also including a colonically absorbable form of levodopa for treating a negative or cognitive symptom in the patient; Levodopa prodrug increase bioavailability, sustained release |
| 03/20/2008 | US20080070983 2-O- (Beta-D-Glucopyranosyl) ascorbic acid, process for its production, and foods and cosmetics containing compositions comprising it |
| 03/20/2008 | US20080070982 System and methods of melanoma prevention |
| 03/20/2008 | US20080070981 Water-soluble compositions of bioactive lipophilic compounds |
| 03/20/2008 | US20080070980 or esters; promoting an increased protein formation and/or prevention of loss of proteins in humans and animals due to an adverse health condition; increased protein formation in sports and workout activities; during aging |
| 03/20/2008 | US20080070979 13,14-dihydro-15-keto-16,16-difluoro-18(S)-methyl-prostaglandin (PGE1); decrease mucosal damage induced by acid, pepsin, nonsteroidal antiinflammatory drugs, and bacterial infection from epithelial surfaces; antiinflammatory agent, microbiocide |
| 03/20/2008 | US20080070978 cloprostenol or latanoprost; topical use; highly crystalline structures that are easy to formulate into ophthalmic solutions; hydrolysis of these analogs does not have toxic and irritant small aliphatic alcohol coproducts; hypotensive agent for intraocular pressure |
| 03/20/2008 | US20080070977 Comprising an emulsifier, a bowel relaxant and one or more chelating agents to absorb and mechanically agitate non-digested fats; decreased side effects |
| 03/20/2008 | US20080070976 Thiophene-2,5-dicarboxylic acid 2-hydroxyamide 5-({1-[4-(4-trifluoromethoxy-benzyloxy)-phenyl]-ethyl}-amide); histone deacetylase inhibitors; anticancer; antiproliferative |
| 03/20/2008 | US20080070975 methylnaltrexone, a calcium salt, chelating agent in aqueous solution; calcium salts of EDTA, DTPA, HEDTA, EGTA, nitrilotriacetic acid or calcium citrate; reducing severity of side effects from use of analgesic opioids; effective delivery without degradation under refrigeration and/or room temperature |
| 03/20/2008 | US20080070974 4-((1E)-2-(((E)-2-fluoro-4-cyanostyrylsulfonyl)methylsulfonyl)vinyl)-3-fluoro-benzonitrile; mitogen activated protein kinase inhibitor; cell growth factor receptor antagonist; angiogenesis inhibitor, antiproliferative and anticarcinogenic agent; neurodegenerative diseases |
| 03/20/2008 | US20080070973 succinate and naphthalenedisulfonate salts and solvates of 2-(Methyloxy)-N-[2-methyl-1-phenyl-2-(1-pyrrolidinyl)propyl]-4,6-bis(trifluoromethyl)benzamide; crystalline; block the glycine site of the NMDA receptors; schizophrenia, dementia, attention deficit disorder; ease of isolation in large scale |
| 03/20/2008 | US20080070972 for an oral cytokine inhibitor of interleukin-1 beta converting enzyme; antiinflammatory agent: rheumatoid arthritis and psoriasis; wet granulated compound with the organic solvent, a first and second binding agent, porous agent, glidant, lubricant |
| 03/20/2008 | US20080070971 Medical Use of Bilirubin and its Structural Analogues |
| 03/20/2008 | US20080070970 Novel indole derivatives as selective androgen receptor modulators (sarms) |
| 03/20/2008 | US20080070969 [3.2.0] heterocyclic compounds and methods of using the same |
| 03/20/2008 | US20080070968 1-(4-fluoro-phenyl)-8-(4-methyl-benzyl)-1,4,5,6,7,8-hexahydro-cycloheptapyrazole-3-carboxylic acid (1,3,3-trimethyl-bicyclo[2.2.1]hept-2-yl)-amide; antidepressant, anxiolytic; nervous system disorders, metabolic disorders, obesity |
| 03/20/2008 | US20080070967 facilitates handling; 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionic acid; methyl 3-[4-(indan-2-yloxy)-3-(1-methyl-1H-indazol-5-yl)-5-nitrophenyl]propionate; crystallization; industrial scale |
| 03/20/2008 | US20080070965 Thiophene-carboxamides useful as inhibitors of protein kinases |
| 03/20/2008 | US20080070964 Opioid receptor active compounds |